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Cummings BP, Stanhope KL, Graham JL, Evans JL, Baskin
DG, Griffen SC, Havel PJ. Dietary fructose accelerates the
development of diabetes in UCD-T2DM rats: amelioration by the
antioxidant, -lipoic acid. Am J Physiol Regul Integr Comp
Physiol 298: R1343–R1350, 2010. First published February 10,
2010; doi:10.1152/ajpregu.00468.2009.—Sustained fructose con-
sumption has been shown to induce insulin resistance and glucose
intolerance, in part, by promoting oxidative stress. Alpha-lipoic acid
(LA) is an antioxidant with insulin-sensitizing activity. The effect of
sustained fructose consumption (20% of energy) on the development
of T2DM and the effects of daily LA supplementation in fructose-fed
University of California, Davis-Type 2 diabetes mellitus (UCD-
T2DM) rats, a model of polygenic obese T2DM, was investigated. At
2 mo of age, animals were divided into three groups: control,
fructose, and fructose  LA (80 mg LA·kg body wt1·day1). One
subset was followed until diabetes onset, while another subset was
euthanized at 4 mo of age for tissue collection. Monthly fasted blood
samples were collected, and an intravenous glucose tolerance test
(IVGTT) was performed. Fructose feeding accelerated diabetes onset
by 2.6  0.5 mo compared with control (P  0.01), without affecting
body weight. LA supplementation delayed diabetes onset in fructose-
fed animals by 1.0  0.7 mo (P  0.05). Fructose consumption
lowered the GSH/GSSG ratio, while LA attenuated the fructose-
induced decrease of oxidative capacity. Insulin sensitivity, as assessed
by IVGTT, decreased in both fructose-fed and fructose  LA-
supplemented rats. However, glucose excursions in fructose-fed LA-
supplemented animals were normalized to those of control via in-
creased glucose-stimulated insulin secretion. Fasting plasma triglyc-
erides were twofold higher in fructose-fed compared with control
animals at 4 mo, and triglyceride exposure during IVGTT was
increased in both the fructose and fructose  LA groups compared
with control. In conclusion, dietary fructose accelerates the onset of
T2DM in UCD-T2DM rats, and LA ameliorates the effects of fructose
by improving glucose homeostasis, possibly by preserving -cell
function.
glucose tolerance; oxidative capacity; dyslipidemia; islet function
SUSTAINED FRUCTOSE CONSUMPTION has been shown to decrease
insulin sensitivity, increase inflammation, and promote dyslip-
idemia, (18, 37–39, 44, 45) and may thereby increase the risk
for development of Type 2 diabetes mellitus (T2DM). Fructose
has also been demonstrated to increase oxidative stress (3, 14,
15, 26, 46, 47), which may contribute to insulin resistance,
islet dysfunction and the development of T2DM (10 –12).
Thus, we hypothesized that sustained fructose consumption
would accelerate the onset of T2DM in University of Cali-
fornia, Davis (UCD)-T2DM rats, a model of T2DM that is
more similar in etiology to T2DM in humans than other
existing rodent models (4).
Because of the increasing prevalence of T2DM, there is a
need to identify new effective strategies for diabetes preven-
tion, including the potential use of nutritional supplements.
Alpha-lipoic acid (LA) is a widely used nutritional supplement
that has antioxidant properties and other insulin-sensitizing
actions (9, 13, 23, 25, 29). LA is a potent, multifunctional
mitochondrial antioxidant with a unique self-regenerating ca-
pacity (1, 28, 43). LA scavenges reactive oxygen species
(ROS), reduces other antioxidants such as vitamins E and C,
chelates metals and repairs oxidized proteins, reduces inflam-
mation and acts as a cofactor for mitochondrial enzymes
responsible for glucose oxidation such as pyruvate dehydroge-
nase (29, 33). Furthermore, LA treatment has been reported to
improve insulin sensitivity in rodent models (7, 25, 35, 36, 46)
and in obese and diabetic humans (19, 24, 30, 31).
We hypothesized that daily LA supplementation would
reduce oxidative stress and ameliorate the accelerated onset of
T2DM in fructose-fed UCD-T2DM rats. Thus, we determined
the time to diabetes onset and assessed oxidative status and
changes of glucose tolerance, glucose-stimulated insulin secre-
tion, and circulating lipids and hormones in three groups of
UCD-T2DM rats: control (chow-fed), fructose-fed (20% of
energy), and fructose  LA (20% of energy from fructose 
80 mg LA·kg body wt1·day1).
METHODS
Diets and animals. The UCD-T2DM rat model was derived by
crossing obese Sprague-Dawley rats prone to adult-onset obesity and
insulin resistance (40, 42) with lean Zucker diabetic fatty (ZDF) rats
that have intact leptin signaling, but a defect in pancreatic -cell
insulin gene transcription (17). This cross resulted in a new rat model
that develops polygenic adult-onset obesity and diabetes in both sexes
with animals exhibiting insulin resistance, impaired glucose tolerance,
and eventual -cell decompensation (4). These animals also demon-
strate a later age of diabetes onset than other rodent models of T2DM,
such as the ZDF rat, making them highly suitable for diabetes
prevention studies (2, 4).
Male rats were housed in hanging wire cages in the animal facility
in the Department of Nutrition at the University of California, Davis,
and maintained on a 12:12-h light-dark cycle. Food intake and body
weight were measured three times a week. Diabetes onset was defined
as a fasting plasma glucose value 125 mg/dl. Animals were moni-
Address for reprint requests and other correspondence: Peter J. Havel, Dept.
of Molecular Biosciences, School of Veterinary Medicine, Univ. of California,
Davis, One Shields Ave., Davis, CA, 95616 (e-mail: pjhavel@ucdavis.edu).
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tored up to 1 yr of age for T2DM onset. The experimental protocols
were approved by the UCD Institutional Animal Care and Use
Committee.
Starting at 2 mo of age, male animals were divided into three
groups: control (n  23), fructose (n  30), and fructose  LA (n 
28). Baseline body weights were 358  4 g, 358  4 g, and 360 
4 g in control, fructose, and fructose  LA animals, respectively. All
animals received a ground rodent chow diet (no. 5012, Ralston Purina,
Belmont, CA) supplemented with safflower oil, such that the percent
energy from fat, protein, and carbohydrate were 27%, 17%, and 56%,
respectively, for all treatment groups. The fructose and fructose LA
groups received fructose at 20% of energy. LA (racemic form; 1:1
ratio of the individual enantiomers; Antibioticos, Rodano, Italy) was
mixed in with the chow to provide a dose of 80 mg LA·kg body
wt1·day1. Blood samples were collected after an overnight fast into
EDTA-treated tubes each month until 8 mo of age for measurement of
glucose, insulin, triglyceride (TG), adiponectin, and leptin. Twelve-
hour urine samples were also collected monthly in sodium azide-
treated flasks and assayed for glucose. At 3.5 mo of age, an intrave-
nous glucose tolerance test was conducted on unanesthetized animals.
Animals were fasted overnight and a 27-gauge butterfly catheter was
placed in the saphenous vein for infusion of a bolus dose of 500 mg/kg
body wt of a 50% dextrose solution. Blood samples were collected
from the tail at 0, 5, 10, 20, 30, 45, 60, 90, 120, and 180 min after
glucose administration. A subset of animals (n  11 per group) were
euthanized at 4 mo of age and tissues were collected for the analyses
described below. Whole blood samples were also collected from this
subset of animals at 2 and 4 mo of age for the measurement of reduced
to oxidized glutathione ratio (GSH/GSSG) in erythrocytes as an index
of oxidative capacity.
Pancreatic immunohistochemistry. Pancreata were dissected under
pentobarbital sodium anesthesia and placed in 4% paraformaldehyde
at 4°C and embedded in paraffin. Sections (6 	M thick) were treated
with 0.3% hydrogen peroxide for 30 min, followed by 5% normal goat
serum in PBS, and then immunostained following a standard protocol
(48). Antibodies used were 1) monoclonal anti-insulin (Sigma I-2018;
Sigma, St. Louis, MO) at 6 	g/ml and 2) monoclonal anti-glucagon
(Sigma G-2654) at 10 	g/ml, 4°C overnight. Detection was by the
ABC Elite kit (Vectastain PK-6100; Vector Laboratories, Burlingame,
CA) and diaminobenzidine-H2O2 (DAB) (Vector SK-4100), and
counterstained in hematoxylin. For a negative control, normal mouse
IgG was substituted (015-000-002; Jackson ImmunoResearch, Bar
Harbor, ME) at 10 	g/ml, and the absence of staining of islet cells was
confirmed. Images were captured using a Nikon CoolScope micro-
scope at 
20 magnification. Original images of immunostained islets
were captured as 16-bit RGB JPEG files. Each full original JPEG file
was globally processed with the Auto Levels function of Adobe
Photoshop to adjust color balance and contrast (no other manipula-
tions were performed on the original image files).
Pancreatic insulin extraction. Pancreatic insulin was extracted
using a combination of methods of Davidson and Haist (5), Dixit et al.
(6), and Karam and Grodsky (21). Preweighed pancreas samples were
minced and sonicated and then incubated overnight at 4°C in acid
alcohol with aprotinin. Samples were centrifuged, and the supernatant
was collected, and the pellet was washed once more with the same
solution. An alcohol diethyl ether solution (38% alcohol, 62% ether)
was added to the supernatants and incubated overnight at 4°C to
precipitate the insulin. Samples were centrifuged, and the pellet was
reconstituted in 0.01 N hydrochloric acid. Samples were analyzed for
insulin content by RIA (Millipore, St. Charles, MO).
Visceral adiposity and liver and muscle TG content. Mesenteric,
subcutaneous, epididymal, and retroperitoneal adipose depots were
dissected and weighed. The liver and gastrocnemius muscle were
dissected and weighed, and samples of each were immediately placed
in liquid nitrogen and stored at 80°C. Liver and muscle TG content
was measured using the Folch method (16) for lipid extraction
followed by spectrophotmetric measurement of TG content (Thermo
Electron, Louisville, CO). One animal from the control group and one
from the fructose group had become diabetic and started losing weight
prior to euthanasia, and thus were excluded from the data set to avoid
the confounding effects of weight loss on tissue TG content and
adiposity.
Mesenteric adipocytes were isolated according to the method of
Rodbell (32), as modified by Mueller et al. (27). Adipose tissue was
minced and incubated with digestion buffer with collagenase at 37°C
with gentle shaking for 30 min. The resulting cell suspension was
diluted with 0.1 M HEPES-phosphate buffer and filtered through a
250-	m nylon mesh screen. The filtered cells were washed once and
centrifuged at 1,000 rpm for 6 min. Immediately following centrifu-
gation, 25 	l of packed adipocytes were added to an Accuvette
containing 20 ml of Isoton (Beckman Coulter, Sykesville, MD). The
Accuvette was immediately capped and gently inverted until the cells
were uniformly dispersed. The Accuvette was quickly placed on the
sampling platform of the MultiSizer III and a 0.5-ml aliquot was
counted and sized through a 280-	m aperture. Using the Multisizer
3.51 software supplied with the Multisizer III, cells were counted and
sorted into 300 size bins in a range of 12-1,200 pl. The percent of total
adipocyte volume was calculated for each bin, and the maximum
value was reported as the peak value.
Assays. Plasma and urine glucose were measured using an enzy-
matic colorimetric assay for glucose (Thermo DMA, Louisville, CO).
Plasma TG was measured using an enzymatic colorimetric assay
(L-type TG H kit, Wako Chemicals, Richmond, VA). Insulin, leptin,
and adiponectin were measured with rodent/rat specific RIAs (Milli-
pore). Plasma insulin in intravenous glucose tolerance test (IVGTT)
samples was measured by rat/mouse insulin ELISA (Millipore) since
small blood samples were collected (200 	l blood per time point),
preventing the use of RIA. Whole blood GSH and GSSG were
measured using an enzymatic colorimetric assay (BIOXYTECH
GSH/GSSG-412; Oxis Research, Portland, OR). Fasting plasma in-
tracellular adhesion molecule 1 (ICAM-1) was measured with an
ELISA for rat sICAM-1 (R&D Systems, Minneapolis, MN).
Statistics and data analysis. Data are presented as means  SE.
Statistical analyses were performed using GraphPad Prism 4.00 for
Windows, GraphPad Software (San Diego, CA). Diabetes prevention
was analyzed by Log-rank testing of Kaplan-Meier survival curves up
to 8 mo of age since 18/19 fructose-fed animals were diabetic by this
age. Longitudinal data were compared by two-factor repeated-mea-
sures ANOVA (time and treatment) followed by post hoc analysis
with Bonferroni’s multiple-comparison test. Mesenteric adipose
weights, mesenteric adipocyte size, and tissue TG results were ana-
lyzed by one-factor ANOVA. For IVGTT data, the area under the
curve was calculated and compared by one-factor ANOVA. Insulin
sensitivity was calculated by dividing the slope of the glucose curve
between 5 and 30 min after glucose infusion by the insulin area under
the curve times 1,000. The 4 mo GSH/GSSG ratios were compared
with baseline values by Student’s t-test. Animals that did not complete
the 8-mo time course were not included in longitudinal analyses.
Differences were considered significant at P  0.05.
Table 1. Average ages of onset and incidence of diabetes in
animals followed 1 yr of age
Control Fructose Fructose  LA
Age of onset, mo 7.4  0.5 4.8  0.5* 5.8  0.7
Incidence, % 92 100 88
n 12 19 17
Values are expressed as means  SE. P  0.05 by one-factor ANOVA; *P 
0.05 compared to control by Bonferroni’s post test. LA, alpha-lipoic acid.
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RESULTS
Effects of fructose and LA on T2DM onset. Chronic con-
sumption of the high-fructose diet accelerated diabetes onset
(P  0.01) with fructose animals developing fasting hypergly-
cemia (fasting plasma glucose 125 mg/dl) 2.6  0.5 mo
earlier than control animals (Table 1). LA supplementation
in fructose-fed rats delayed T2DM onset by 1.0  0.7 mo
compared with animals consuming fructose alone (P  0.05)
(Fig. 1). Despite these differences in T2DM onset, groups did
not differ in energy intake or body weight (Fig. 2). At 4 mo of
Fig. 1. Kaplan-Meier analysis of diabetes incidence in control (n  12),
fructose (n  19), and fructose  alpha-lipoic acid (LA) (n  17) groups.
*P  0.05, **P  0.01 by log-rank test compared with fructose.
Fig. 2. Weekly mean energy intake (A) and body weight (B) in control (n 
12), fructose (n  18), and fructose  LA (n  16) groups. Values are
expressed as means  SE.
Fig. 3. Plasma glucose (A), insulin (B), and triglycerides (TG) (C) excursions
following intravenous glucose administration (500 mg/kg body wt, 50%
dextrose solution) in control (n  15), fructose (n  20), and fructose  LA
(n  18) prediabetic rats at 3.5 mo of age. Values are expressed as means 
SE. *P 0.05 compared with fructose, **P 0.05 compared with control and
fructose  LA, ***P 0.05 compared with control by one-factor ANOVA.
For TG values, control: n  13, fructose: n  19, fructose  LA: n  17.
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age, average energy intake was control  109  3 kcal/day,
fructose  108  3 kcal/day, fructose  LA  107  6
kcal/day, and average body weights were control  578  16
g, fructose  596  9 g, fructose  LA  579  7 g. There
was a tendency for fructose rats to have higher energy intake
starting at 6 mo of age. By this age, 16 of the 19 fructose-fed
animals had developed diabetes and were, therefore, develop-
ing diabetic hyperphagia. Average urine glucose values at 6 mo
of age were control  1,683  650 mg/dl, fructose  3,080 
723 mg/dl, fructose  LA  1,735  574 mg/dl.
Effects of fructose and alpha-lipoic acid on glucose toler-
ance and lipids. Insulin sensitivity (IS), as assessed by IVGTT,
was significantly lower in fructose and fructose  LA animals
compared with control animals (IS: control  0.42  0.11,
fructose  0.087  0.10, fructose  LA  0.13  0.14,
P  0.05). However, fructose  LA animals were able to
maintain lower glucose excursions, similar to control animals,
by increasing insulin secretion in response to glucose, resulting
in larger insulin excursions [area under the curve (AUC)
control  42,637  1,602, fructose  48,760  2,027,
fructose  LA  41,234  1,561 mg/dl 
 180 min, P  0.05
fructose compared with control and fructose  LA] (Fig. 3A).
Insulin excursions between baseline and 60 min after glucose
administration were higher in fructose  LA animals com-
pared with fructose-fed animals (AUC: control 224  24,
fructose 215  17, fructose  LA  277  33 ng/ml 
 60
min, P  0.05), suggestive of preservation of islet/-cell
function (Fig. 3B). TG exposure during IVGTT was increased
in fructose-fed and fructose  LA groups compared with
control (AUC: control 14,929 1,923, fructose 21,680
2,269, fructose  LA  22,987  2,381 mg/dl 
 180 min,
P  0.05), further indicating the presence of insulin resistance
in both the fructose and fructose  LA animals (Fig. 3C).
Longitudinal measurements of metabolites and hormones.
Consistent with the observed delay in T2DM onset, fasting
plasma glucose concentrations were significantly higher in fruc-
tose-fed animals compared with both control and fructose  LA
animals, particularly at 8 mo of age, at which time 18 of the 19
fructose animals had developed overt diabetes (Fig. 4A, P 
0.05). Fructose consumption tended to result in higher fasting
plasma insulin concentrations compared with control animals,
and this effect was mitigated by simultaneous LA supplemen-
tation (Fig. 4B). Fasting plasma TG concentrations were almost
twofold higher in fructose-fed animals compared with control
animals at 4 mo of age (P  0.001), whereas fasting plasma
TG levels only tended to be elevated in fructose  LA animals
Fig. 4. Monthly fasting plasma glucose (A),
insulin (B), TG (C), adiponectin (D), and
leptin (E) concentrations in control (n  12),
fructose (n 18), and fructose LA (n 16)
aniamls. Values are expressed as means 
SE. ***P  0.001 by Bonferroni’s posttest
compared with control; *P0.05 by Bonfer-
roni’s posttest compared with control and
fructose  LA (A).***P  0.001 by two-
factor repeated measures ANOVA compared
with control and fructose  LA; **P 
0.001 by two-factor repeated measures
ANOVA compared with control (C).
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compared with control (Fig. 4C). The majority of animals in
the fructose group (11 out of 19) were prediabetic at this age,
demonstrating the development of fasting hypertriglyceridemia
prior to T2DM onset in fructose-fed rats. There were no
significant differences in fasting plasma adiponectin or leptin
concentrations between treatment groups over the course of the
study (Fig. 4, D and E).
The GSH/GSSG ratio was significantly lowered compared
with baseline values in fructose animals, but this ratio re-
mained stable in both control and fructose  LA animals
(%GSH/GSSG from initial: control  9  15, fructose 
19 4, fructose LA8 7) (Table 2). Fasting plasma
sICAM-1 concentrations were elevated in fructose-fed and
fructose  LA rats compared with control rats at 5 mo of age
but did not differ between fructose  LA and fructose-fed rats
(Table 3).
Visceral adiposity and tissue TG content. Body weight, fat
depot weights, organ weight, and mesenteric adipocyte size did
not differ between groups (Table 4). Liver and muscle TG
content did not differ between groups but tended to be higher
in the fructose  LA group.
Pancreatic immunohistochemistry and insulin content. Im-
munostaining for insulin and glucagon was performed on a
subset of six animals per group to assess islet morphology.
Fig. 5 presents representative images of control, fructose-fed,
and fructose  LA-treated animals. Generally, islets from
control and fructose  LA-treated animals appeared to be
smaller with less infiltration than islets from animals that
received the high-fructose diet alone. Despite these morpho-
logic differences, insulin content measured in pancreases from
prediabetic animals killed at 4 mo of age was not different
between groups (Table 3).
DISCUSSION
In this study, we demonstrated that chronic fructose con-
sumption accelerates the onset of diabetes by reducing insulin
sensitivity and glucose tolerance and by promoting dyslipide-
mia, oxidative stress, and inflammation in UCD-T2DM rats.
Furthermore, supplementation with LA in fructose-fed rats
ameliorates the acceleration of diabetes onset and improves
glucose tolerance, glucose-stimulated insulin secretion, and
oxidative capacity, without decreasing body weight or affect-
ing triglycerides. Together, these results are supportive of an
important role for oxidative stress in the ability of fructose to
hasten the onset of diabetes in UCD-T2DM rats.
The mechanism by which sustained fructose consumption
reduces insulin sensitivity and glucose tolerance, thus predis-
posing individuals to development of T2DM, is not estab-
lished. It has been suggested that fructose reduces insulin
sensitivity by providing a direct source of intrahepatic triglyc-
eride via de novo lipogenesis (39, 41). Alternatively, it has also
been suggested that fructose-induced hepatic insulin resistance
is a product of increased hepatic stress signaling (47). Despite
the observed increases of fasting plasma TG in response to
fructose feeding, liver and muscle TG content were not in-
creased in fructose-fed UCD-T2DM rats. Thus, induction of
oxidative stress is a potential mechanism by which dietary
fructose decreases insulin sensitivity in UCD-T2DM rats. This
is supported by the observation that the GSH/GSSG ratio was
significantly decreased only in the animals consuming fructose
without LA supplementation. GSH is a key metabolite in the
maintenance of the cellular redox state, and GSSG is its
oxidized counterpart. Thus, maintaining higher GSH relative to
GSSG levels is important in the protection of cell membranes
from free radicals (20). The loss in oxidative capacity may, in
part, explain the observed decreases of glucose tolerance and
insulin sensitivity in fructose-fed animals. Fructose consump-
tion has been reported to increase production of reactive
metabolites, which can activate pathways, such as c-Jun-N-
Table 2. Oxidized and reduced glutathione concentrations in whole blood samples
Control Fructose Fructose  LA
Age, mo 2 4 2 4 2 4
GSH, 	M 2736  239 1904  148 2607  166 1703  113 2636  176 2211  125*
GSSG, 	M 69  4 61  4 71  3 59  3 73  2 69  3*
GSH/GSSG 38 3 31  3 35  2 27  1** 34  2 31  2
Values are expressed as means  SE; P  0.05 by one-factor ANOVA, *P  0.05 compared to fructose by Bonferroni’s post test and **P  0.05 compared
to baseline (2-mo) ratio by Student’s t-test. Excludes animals that became diabetic and began losing weight before 4 mo of age. Control: n  10, fructose:
n  10, fructose  LA: n  11.
Table 4. Tissue weights and TG deposition, mesenteric
adipocyte size, and pancreatic insulin content at 2 mo into
intervention
Control Fructose Fructose  LA
BW, g 566  10 568  10 561  10
Epididymal fat, g 9.7 0.5 10.0  0.5 9.9  0.5
Retroperitoneal fat, g 12.7 0.5 12.7  1.1 11.6  0.5
Mesenteric fat, g 10.4 0.4 11.4  0.7 10.7  0.6
Subcutaneous fat, g 49 3 50  3 52  3
Total white adipose tissue, g 82  4 84  4 84  4
Heart, g 1.48 0.03 1.49  0.06 1.43  0.03
Kidney, g 1.60 0.04 1.62  0.06 1.66  0.05
Liver, g 19.1 0.7 19.3  0.8 20.5  0.7
Liver TG, mg/g 32.7 1.7 31.3  3.4 42.5  4.4
Muscle TG, mg/g 4.9 1.2 3.7  0.4 6.3  1.1
Peak mesenteric adipocyte
size, pl
485  35 487  21 531  39
Pancreatic insulin content,
	g/g
47  9 45  6 47  5
Values are expressed as means  SE. Control: n  10, Fructose: n  10,
Fructose  LA: n  11. For pancreatic insulin content, Control: n  4,
Fructose: n  5, Fructose  LA: n  5.
Table 3. Fasting plasma sICAM-1 concentrations
Two Months, ng/ml Five Months, ng/ml n
Control 17.7 0.7 21.3  1.1 12
Fructose 16.9 0.6 29.6  3.6* 19
Fructose  LA 16.8 0.5 31.0  4.0* 17
Values are expressed as means  SE. One-factor ANOVA, *P  0.05
compared to Control by Bonferroni’s post test.
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terminal kinase and nuclear factor-B pathways that result in
serine phosphorylation of the insulin receptor and insulin
receptor substrate proteins, resulting in decreased insulin sen-
sitivity (12). Furthermore, the lack of a compensatory increase
of the insulin response to glucose during IVGTT in the animals
consuming fructose alone suggests -cell dysfunction, which
may be a result of oxidative stress at the level of the islet/-cell
(10, 11). It has been well documented that elevated circulating
lipids can increase oxidative stress in -cells and that with
impaired oxidative regenerative capacity, this can lead to
-cell dysfunction and damage (11).
A role for oxidative stress in the acceleration of T2DM onset
by fructose consumption in the UCD-T2DM rat is further
strengthened by the effects of LA treatment in fructose-fed
rats. We used a lower dose of LA to investigate the antioxidant
properties of LA in the presence of fructose-induced oxidative
stress, independent of its previously reported effects to de-
crease food intake and body weight (23, 34, 36). As in the
control group, the animals consuming fructose that received
supplemental LA did not exhibit a significant decrease of the
GSH/GSSG ratio after 2 mo of treatment. This improvement in
oxidative capacity was reflected in the IVGTT profile, as
fructose  LA animals were able to maintain glucose excur-
sions similar to control animals via increased insulin responses
during the first 60 min after intravenous glucose administra-
tion, despite the presence of insulin resistance induced by
chronic fructose consumption. Thus, LA supplementation ap-
pears to improve glucose-stimulated insulin secretion in fruc-
tose-fed rats. The preservation of islet function was supported
by pancreatic immunohistochemistry, in which smaller islets
with less infiltration were observed in control animals and
fructose-fed animals receiving LA compared with the animals
consuming fructose alone. Furthermore, the delay in onset in
the animals supplemented with LA cannot be attributed to
improved insulin sensitivity. LA has been suggested to im-
prove insulin sensitivity by decreasing ectopic TG deposition
and increasing AMP kinase expression in some studies (25,
36). However, differences in muscle or liver TG content,
mesenteric adipocyte size, and circulating adiponectin concen-
trations were not observed in the present study. It is possible
that reductions of food intake and body weight gain reported
with higher doses of LA contributed to the previously observed
effects of LA to improve insulin sensitivity (25, 36).
Despite the widespread use of LA, only one other study has
been conducted to assess the effects of LA to prevent/delay the
onset of Type 2 diabetes (36). In this study, LA supplementa-
tion completely prevented diabetes onset (compared with 78%
diabetes incidence in untreated rats) in Otsuka Long-Evans
Fig. 5. Representative images of pancreas sections from control, fructose-fed, and fructose  LA supplemented animals at 4 mo of age. Hematoxylin-and-eosin
stain for control (A) fructose, (B) and fructose  LA (C). Anti-insulin immunostaining for control (D), fructose (E), fructose  LA animals (F). Anti-glucagon
immunostaining for control (G), fructose (H), and fructose  LA (I).
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Tokushima Fatty rats, a rat model in which obesity and diabe-
tes are thought to result, in part, from a mutation in the gene
encoding the CCK-A receptor (22). The present study was
conducted in a rat model with polygenic adult-onset obesity
and diabetes, which is more similar to the etiology of T2DM in
human populations (4). Furthermore, this previous study (22)
employed a substantially higher dose of LA (200 mg·kg body
wt1·day1), which resulted in decreases of both food intake
and body weight.
In summary, fructose feeding accelerates the onset of Type
2 diabetes, and concurrently decreases glucose tolerance, in-
sulin sensitivity, and oxidative capacity compared with UCD-
T2DM rats fed a standard rodent chow diet. It would also be of
interest to determine whether fructose feeding accelerates di-
abetes onset compared with a glucose-fed control group. Sup-
plementation with the antioxidant, LA, attenuated many of the
effects of fructose consumption. This observation is supportive
of a role for oxidative stress in the effects of dietary fructose to
induce insulin resistance and accelerate the development of
diabetes. Together, these data indicate the need for additional
investigation of effects of antioxidants, such as LA, on glucose
metabolism and islet/-cell function and the prevention of
T2DM (8). The potential for antioxidants to delay the onset of
T2DM in human populations is important since delaying the
onset of diabetes by even a few years, would similarly delay
the development of complications of diabetes, including reti-
nopathy, nephropathy, neuropathy, and macrovascular disease.
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